scholarly journals Evaluation of Mycophenolate Mofetil and Low-Dose Steroid Combined Therapy in Moderately Severe Henoch-Schönlein Purpura Nephritis

2017 ◽  
Vol 23 ◽  
pp. 2333-2339 ◽  
Author(s):  
Zhihong Lu ◽  
Junfeng Song ◽  
Jianhua Mao ◽  
Yonghui Xia ◽  
Caiyun Wang
Keyword(s):  
Mycophenolate Mofetil ◽  
Low Dose ◽  
Combined Therapy ◽  
Henoch Schonlein Purpura ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura ◽  
Purpura Nephritis

Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil

2011 ◽  
Vol 27 (5) ◽  
pp. 765-771 ◽  
Author(s):  
Yue Du ◽  
Ling Hou ◽  
Chengguang Zhao ◽  
Mei Han ◽  
Yubin Wu
Keyword(s):  
Mycophenolate Mofetil ◽  
Henoch Schonlein Purpura ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura ◽  
Purpura Nephritis

scholarly journals Treatment of severe henoch-schonlein purpura nephritis with mycophenolate mofetil

2014 ◽  
Vol 25 (4) ◽  
pp. 858 ◽  
Author(s):  
AhmadAli Nikibakhsh ◽  
Hashem Mahmoodzadeh ◽  
Mohamad Karamyyar ◽  
Sasan Hejazi ◽  
Mehran Noroozi ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Henoch Schonlein Purpura ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura ◽  
Purpura Nephritis

scholarly journals Biopsy-proven Henoch-Schönlein purpura nephritis: a single center experience

2020 ◽  
Author(s):  
Eda Didem Kurt-Şükür ◽  
Thivya Sekar ◽  
Kjell Tullus
Keyword(s):  
Angiotensin Receptor Blockers ◽  
Laboratory Data ◽  
Treatment Modalities ◽  
Oxford Classification ◽  
Henoch Schonlein Purpura ◽  
Nephritic Syndrome ◽  
Kidney Involvement ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura ◽  
Purpura Nephritis

Abstract Background Knowledge on normal progress and treatment of Henoch-Schönlein purpura nephritis (HSPN) is limited. This study reviews outcome, clinical, pathological, and therapeutic factors affecting the prognosis of HSPN patients. Methods Forty-nine children with biopsy-confirmed HSPN diagnosed between September 2008 and 2018 were included. Demographics, clinical and laboratory data, treatment, and outcome were recorded at the time of biopsy, 3, 6, 12, and 24 months and at last visit. Clinical outcome was graded according to Meadow’s criteria. Results The median age at time of biopsy was 10.1 years (IQR:5.7) and female/male ratio 24/25. At presentation, 40.8% of patients had nonnephrotic proteinuria, 18.4% nephrotic syndrome (NS), 4.1% nephritic syndrome (NephrS), and 36.7% NephrS+NS. There were 11 patients with an estimated glomerular filtration rate below 90 ml/min/1.73 m2. Biopsy specimens were classified according to International Study of Kidney Diseases in Children (ISKDC) and Oxford Classification MEST-C scoring systems. Forty-one patients received angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, 37 patients steroids, and 35 patients other immunosuppressive medications. At last visit, 24 patients had stage 1 chronic kidney disease (CKD), three stage 2 CKD, and two had stage 5 CKD. Neither clinical parameters nor ISKDC biopsy grade or treatment modalities effected the final outcome. The Oxford classification showed significantly increased segmental glomerulosclerosis in patients with unfavorable outcome. Favorable outcome was associated with shorter time from kidney involvement to biopsy and start of treatment. Conclusion A large proportion of patients continued to show signs of CKD at last follow-up while only a small proportion developed stage 5 CKD.

Sign in / Sign up

Export Citation Format

Share Document